Vertex New CF Combo Addresses More Patients, With Daily Dosing

 
• By Joseph Haas

Vertex hopes to convert CF patients to new combo Alyftrek from Trikafta with once-daily dosing. Approved on 20 December, the new triplet has longer patent protection and 7% higher US pricing.

Vertex HQ, Boston
Vertex obtained US FDA approval for new CF combo product Alyftrek

More from New Products

More from Therapy Areas